# Predictive Value of Tumor Vascular Normalization Scoring in HER-2 Positive Breast Cancer

> **NCT06868758** · — · ACTIVE_NOT_RECRUITING · sponsor: **Chongqing General Hospital** · enrollment: 50 (estimated)

## Conditions studied

- HER2 Positive Breast Carcinoma
- Neoadjuvant Therapy

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06868758
- **Lead sponsor:** Chongqing General Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06868758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06868758, "Predictive Value of Tumor Vascular Normalization Scoring in HER-2 Positive Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06868758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*